Clinical Trial Update: A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects [Phase 2]

View source ↗

Summary

Phase 2 trial updates the assessment of EDP-938 for treating acute upper respiratory tract infection caused by Respiratory Syncytial Virus; results have been po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• EDP-938 (EDP-938)

Snippet

Sponsor: Enanta Pharmaceuticals, Inc | Conditions: Respiratory Syncytial Virus | Phase 2 | Status: COMPLETED | Results posted: 2023-10-30